Walleye Capital’s MoonLake Immunotherapeutics MLTX Stock Holding History

Walleye Capital’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.81M	Sell	246,869 -73,603	-23%	-$1.33M	0.02%	852
2026 Q1	$5.97M	Buy	320,472 +244,720	+323%	+$4.05M	0.02%	695
2025 Q4	$998K	Buy	+75,752	New	+$894K	﹤0.01%	2433
2025 Q2	–	Sell	-26,764	Closed	-$1.05M	–	4847
2025 Q1	$1.05M	Sell	26,764 -182,132	-87%	-$7.85M	﹤0.01%	1938
2024 Q4	$11.3M	Buy	+208,896	New	+$10.7M	0.03%	559
2024 Q3	–	Sell	-86,278	Closed	-$4.04M	–	5666
2024 Q2	$3.79M	Sell	86,278 -50,151	-37%	-$2.12M	0.01%	1509
2024 Q1	$6.85M	Buy	+136,429	New	+$7.4M	0.01%	1083
2023 Q4	–	Sell	-67,926	Closed	-$3.87M	–	5300
2023 Q3	$3.87M	Buy	+67,926	New	+$3.75M	0.01%	1220

Other funds holding MLTX

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jupiter Topco New York $245B AUM

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Walleye Capital's MLTX Position: Q2 2026 in Review

Walleye Capital reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q2 2026, selling an estimated $1.33M and leaving 246,869 shares worth $4.81M. The position accounts for 0.02% of the portfolio, ranked #852.

Walleye Capital first reported a position in MLTX in Q3 2023 and has held it in 8 quarters since. The position peaked at $11.3M in Q4 2024. 172 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

Walleye Capital held 246,869 shares of MoonLake Immunotherapeutics worth $4.81M as of Q2 2026.
Walleye Capital sold 73,603 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.33M.
MoonLake Immunotherapeutics made up 0.02% of Walleye Capital's portfolio in Q2 2026, its #852 holding.
Walleye Capital first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 8 quarters since.
Walleye Capital's MoonLake Immunotherapeutics position peaked at $11.3M in Q4 2024.
172 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.